schliessen

Filtern

 

Bibliotheken

Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs

Human immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the... Full description

Journal Title: Acta neuropathologica 2001, Vol.101 (2), p.85-91
Main Author: CZUB, S
Other Authors: KOUTSILIERI, E , GOSZTONYI, G , RIEDERER, P , TER MEULEN, V , SOPPER, S , CZUB, M , STAHL-HENNIG, C , MÜLLER, J. G , PEDERSEN, V , GSELL, W , HEENEY, J. L , GERLACH, M
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: Berlin: Springer
ID: ISSN: 0001-6322
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_18210583
title: Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs
format: Article
creator:
  • CZUB, S
  • KOUTSILIERI, E
  • GOSZTONYI, G
  • RIEDERER, P
  • TER MEULEN, V
  • SOPPER, S
  • CZUB, M
  • STAHL-HENNIG, C
  • MÜLLER, J. G
  • PEDERSEN, V
  • GSELL, W
  • HEENEY, J. L
  • GERLACH, M
subjects:
  • AIDS Dementia Complex - drug therapy
  • AIDS Dementia Complex - pathology
  • AIDS Dementia Complex - physiopathology
  • Animals
  • Biological and medical sciences
  • Central Nervous System - drug effects
  • Central Nervous System - pathology
  • Central Nervous System - physiopathology
  • Dendrites - drug effects
  • Dendrites - pathology
  • Disease Models, Animal
  • Dopamine - metabolism
  • Dopamine Agonists - adverse effects
  • dopaminergic drugs
  • Dose-Response Relationship, Drug
  • Encephalitis, Viral - drug therapy
  • Encephalitis, Viral - pathology
  • Encephalitis, Viral - physiopathology
  • Human immunodeficiency virus
  • Human viral diseases
  • Infectious diseases
  • Macaca mulatta
  • Medical sciences
  • Neuroprotective Agents - adverse effects
  • Selegiline - adverse effects
  • Simian Acquired Immunodeficiency Syndrome - drug therapy
  • Simian Acquired Immunodeficiency Syndrome - pathology
  • Simian Acquired Immunodeficiency Syndrome - physiopathology
  • Simian immunodeficiency virus
  • Simian Immunodeficiency Virus - drug effects
  • Simian Immunodeficiency Virus - physiology
  • Time Factors
  • Vacuoles - drug effects
  • Vacuoles - pathology
  • Viral diseases
  • Viral diseases of the lymphoid tissue and the blood. Aids
  • Virus Replication - drug effects
  • Virus Replication - physiology
ispartof: Acta neuropathologica, 2001, Vol.101 (2), p.85-91
description: Human immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the asymptomatic SIV infection dopamine (DA) deficits are early components of central nervous system (CNS) dysfunction. To investigate the role of the DA system in SIV infection and to restore the DA deficiency, we administered selegiline, an agent with DAergic and neuroprotective properties, to SIV-infected monkeys. Selegiline increased DA availability but induced CNS vacuolization, SIV encephalitic lesions, and enhanced CNS viral replication during early SIV infection. The pathological changes seem to be mediated by DA, as treatment with L-DOPA, the precursor of DA, had similar effects. We propose that any natural or induced DAergic dysregulation which results in increased DA availability may potentiate HIV-associated neurological disease (ND). Our findings raise new questions regarding the pathogenesis of HIV-ND and generate concerns about the safety of dopaminergic drugs in the clinical management of HIV-infected patients.
language: eng
source:
identifier: ISSN: 0001-6322
fulltext: no_fulltext
issn:
  • 0001-6322
  • 1432-0533
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.136946
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_proquest_miscellaneous_18210583
sourceformatXML
sourcesystemPC
sourcerecordid18210583
originalsourceidFETCH-LOGICAL-p281t-af631a29490df4140d84bb853229ee9cb36f49005beec1a2927802702fbdd8ad0
addsrcrecordideNo9kEtLxDAUhYMoOj6WbiUguKveJH2kSxFfILjR9ZAmN2OkSWvSDvTfG3F0dV_fPXAOIecMrhlAc5MASsgdgGBij6xYKXgBlRD7ZJWXrKgF50fkOKXPPPGmrA7JEcsNE02zItv78KGCRo9hooOlOteoehowboc50bSkCT0d1fQx9MNmoS5QVLFfaHLeqUCd93MYDFqnHQa90K2L-c8Fi3pyQ6DdQs0wKu-y5MZpauK8SafkwKo-4dmunpD3h_u3u6fi5fXx-e72pRi5ZFOhbC2Y4m3ZgrElK8HIsutklS21iK3uRG3zDaoOUf-AvJHAG-C2M0YqAyfk6ld3jMPXjGlae5c09r0KmO2tmeQMKikyeLED586jWY_ReRWX9V9SGbjcASpp1duYU3Ppn5N13UoO3wJbeXY
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid18210583
display
typearticle
titleEnhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs
creatorCZUB, S ; KOUTSILIERI, E ; GOSZTONYI, G ; RIEDERER, P ; TER MEULEN, V ; SOPPER, S ; CZUB, M ; STAHL-HENNIG, C ; MÜLLER, J. G ; PEDERSEN, V ; GSELL, W ; HEENEY, J. L ; GERLACH, M
creatorcontribCZUB, S ; KOUTSILIERI, E ; GOSZTONYI, G ; RIEDERER, P ; TER MEULEN, V ; SOPPER, S ; CZUB, M ; STAHL-HENNIG, C ; MÜLLER, J. G ; PEDERSEN, V ; GSELL, W ; HEENEY, J. L ; GERLACH, M
descriptionHuman immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the asymptomatic SIV infection dopamine (DA) deficits are early components of central nervous system (CNS) dysfunction. To investigate the role of the DA system in SIV infection and to restore the DA deficiency, we administered selegiline, an agent with DAergic and neuroprotective properties, to SIV-infected monkeys. Selegiline increased DA availability but induced CNS vacuolization, SIV encephalitic lesions, and enhanced CNS viral replication during early SIV infection. The pathological changes seem to be mediated by DA, as treatment with L-DOPA, the precursor of DA, had similar effects. We propose that any natural or induced DAergic dysregulation which results in increased DA availability may potentiate HIV-associated neurological disease (ND). Our findings raise new questions regarding the pathogenesis of HIV-ND and generate concerns about the safety of dopaminergic drugs in the clinical management of HIV-infected patients.
identifier
0ISSN: 0001-6322
1EISSN: 1432-0533
2DOI: 10.1007/s004010000313
3PMID: 11271377
4CODEN: ANPTAL
languageeng
publisherBerlin: Springer
subjectAIDS Dementia Complex - drug therapy ; AIDS Dementia Complex - pathology ; AIDS Dementia Complex - physiopathology ; Animals ; Biological and medical sciences ; Central Nervous System - drug effects ; Central Nervous System - pathology ; Central Nervous System - physiopathology ; Dendrites - drug effects ; Dendrites - pathology ; Disease Models, Animal ; Dopamine - metabolism ; Dopamine Agonists - adverse effects ; dopaminergic drugs ; Dose-Response Relationship, Drug ; Encephalitis, Viral - drug therapy ; Encephalitis, Viral - pathology ; Encephalitis, Viral - physiopathology ; Human immunodeficiency virus ; Human viral diseases ; Infectious diseases ; Macaca mulatta ; Medical sciences ; Neuroprotective Agents - adverse effects ; Selegiline - adverse effects ; Simian Acquired Immunodeficiency Syndrome - drug therapy ; Simian Acquired Immunodeficiency Syndrome - pathology ; Simian Acquired Immunodeficiency Syndrome - physiopathology ; Simian immunodeficiency virus ; Simian Immunodeficiency Virus - drug effects ; Simian Immunodeficiency Virus - physiology ; Time Factors ; Vacuoles - drug effects ; Vacuoles - pathology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virus Replication - drug effects ; Virus Replication - physiology
ispartofActa neuropathologica, 2001, Vol.101 (2), p.85-91
rights2001 INIST-CNRS
lds50peer_reviewed
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=866982$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11271377$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0CZUB, S
1KOUTSILIERI, E
2GOSZTONYI, G
3RIEDERER, P
4TER MEULEN, V
5SOPPER, S
6CZUB, M
7STAHL-HENNIG, C
8MÜLLER, J. G
9PEDERSEN, V
10GSELL, W
11HEENEY, J. L
12GERLACH, M
title
0Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs
1Acta neuropathologica
addtitleActa Neuropathol
descriptionHuman immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the asymptomatic SIV infection dopamine (DA) deficits are early components of central nervous system (CNS) dysfunction. To investigate the role of the DA system in SIV infection and to restore the DA deficiency, we administered selegiline, an agent with DAergic and neuroprotective properties, to SIV-infected monkeys. Selegiline increased DA availability but induced CNS vacuolization, SIV encephalitic lesions, and enhanced CNS viral replication during early SIV infection. The pathological changes seem to be mediated by DA, as treatment with L-DOPA, the precursor of DA, had similar effects. We propose that any natural or induced DAergic dysregulation which results in increased DA availability may potentiate HIV-associated neurological disease (ND). Our findings raise new questions regarding the pathogenesis of HIV-ND and generate concerns about the safety of dopaminergic drugs in the clinical management of HIV-infected patients.
subject
0AIDS Dementia Complex - drug therapy
1AIDS Dementia Complex - pathology
2AIDS Dementia Complex - physiopathology
3Animals
4Biological and medical sciences
5Central Nervous System - drug effects
6Central Nervous System - pathology
7Central Nervous System - physiopathology
8Dendrites - drug effects
9Dendrites - pathology
10Disease Models, Animal
11Dopamine - metabolism
12Dopamine Agonists - adverse effects
13dopaminergic drugs
14Dose-Response Relationship, Drug
15Encephalitis, Viral - drug therapy
16Encephalitis, Viral - pathology
17Encephalitis, Viral - physiopathology
18Human immunodeficiency virus
19Human viral diseases
20Infectious diseases
21Macaca mulatta
22Medical sciences
23Neuroprotective Agents - adverse effects
24Selegiline - adverse effects
25Simian Acquired Immunodeficiency Syndrome - drug therapy
26Simian Acquired Immunodeficiency Syndrome - pathology
27Simian Acquired Immunodeficiency Syndrome - physiopathology
28Simian immunodeficiency virus
29Simian Immunodeficiency Virus - drug effects
30Simian Immunodeficiency Virus - physiology
31Time Factors
32Vacuoles - drug effects
33Vacuoles - pathology
34Viral diseases
35Viral diseases of the lymphoid tissue and the blood. Aids
36Virus Replication - drug effects
37Virus Replication - physiology
issn
00001-6322
11432-0533
fulltextfalse
rsrctypearticle
creationdate2001
recordtypearticle
recordideNo9kEtLxDAUhYMoOj6WbiUguKveJH2kSxFfILjR9ZAmN2OkSWvSDvTfG3F0dV_fPXAOIecMrhlAc5MASsgdgGBij6xYKXgBlRD7ZJWXrKgF50fkOKXPPPGmrA7JEcsNE02zItv78KGCRo9hooOlOteoehowboc50bSkCT0d1fQx9MNmoS5QVLFfaHLeqUCd93MYDFqnHQa90K2L-c8Fi3pyQ6DdQs0wKu-y5MZpauK8SafkwKo-4dmunpD3h_u3u6fi5fXx-e72pRi5ZFOhbC2Y4m3ZgrElK8HIsutklS21iK3uRG3zDaoOUf-AvJHAG-C2M0YqAyfk6ld3jMPXjGlae5c09r0KmO2tmeQMKikyeLED586jWY_ReRWX9V9SGbjcASpp1duYU3Ppn5N13UoO3wJbeXY
startdate2001
enddate2001
creator
0CZUB, S
1KOUTSILIERI, E
2GOSZTONYI, G
3RIEDERER, P
4TER MEULEN, V
5SOPPER, S
6CZUB, M
7STAHL-HENNIG, C
8MÜLLER, J. G
9PEDERSEN, V
10GSELL, W
11HEENEY, J. L
12GERLACH, M
generalSpringer
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
77U9
8H94
sort
creationdate2001
titleEnhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs
authorCZUB, S ; KOUTSILIERI, E ; GOSZTONYI, G ; RIEDERER, P ; TER MEULEN, V ; SOPPER, S ; CZUB, M ; STAHL-HENNIG, C ; MÜLLER, J. G ; PEDERSEN, V ; GSELL, W ; HEENEY, J. L ; GERLACH, M
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-p281t-af631a29490df4140d84bb853229ee9cb36f49005beec1a2927802702fbdd8ad0
rsrctypearticles
prefilterarticles
languageeng
creationdate2001
topic
0AIDS Dementia Complex - drug therapy
1AIDS Dementia Complex - pathology
2AIDS Dementia Complex - physiopathology
3Animals
4Biological and medical sciences
5Central Nervous System - drug effects
6Central Nervous System - pathology
7Central Nervous System - physiopathology
8Dendrites - drug effects
9Dendrites - pathology
10Disease Models, Animal
11Dopamine - metabolism
12Dopamine Agonists - adverse effects
13dopaminergic drugs
14Dose-Response Relationship, Drug
15Encephalitis, Viral - drug therapy
16Encephalitis, Viral - pathology
17Encephalitis, Viral - physiopathology
18Human immunodeficiency virus
19Human viral diseases
20Infectious diseases
21Macaca mulatta
22Medical sciences
23Neuroprotective Agents - adverse effects
24Selegiline - adverse effects
25Simian Acquired Immunodeficiency Syndrome - drug therapy
26Simian Acquired Immunodeficiency Syndrome - pathology
27Simian Acquired Immunodeficiency Syndrome - physiopathology
28Simian immunodeficiency virus
29Simian Immunodeficiency Virus - drug effects
30Simian Immunodeficiency Virus - physiology
31Time Factors
32Vacuoles - drug effects
33Vacuoles - pathology
34Viral diseases
35Viral diseases of the lymphoid tissue and the blood. Aids
36Virus Replication - drug effects
37Virus Replication - physiology
toplevelpeer_reviewed
creatorcontrib
0CZUB, S
1KOUTSILIERI, E
2GOSZTONYI, G
3RIEDERER, P
4TER MEULEN, V
5SOPPER, S
6CZUB, M
7STAHL-HENNIG, C
8MÜLLER, J. G
9PEDERSEN, V
10GSELL, W
11HEENEY, J. L
12GERLACH, M
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7Virology and AIDS Abstracts
8AIDS and Cancer Research Abstracts
jtitleActa neuropathologica
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0CZUB, S
1KOUTSILIERI, E
2GOSZTONYI, G
3RIEDERER, P
4TER MEULEN, V
5SOPPER, S
6CZUB, M
7STAHL-HENNIG, C
8MÜLLER, J. G
9PEDERSEN, V
10GSELL, W
11HEENEY, J. L
12GERLACH, M
formatjournal
genrearticle
ristypeJOUR
atitleEnhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs
jtitleActa neuropathologica
addtitleActa Neuropathol
date2001
risdate2001
volume101
issue2
spage85
epage91
pages85-91
issn0001-6322
eissn1432-0533
codenANPTAL
abstractHuman immunodeficiency virus infection (HIV) at late stages of the disease is accompanied by neurological complications, including motor, behavioral and cognitive impairment. Using simian immunodeficiency virus (SIV)-infected rhesus monkeys, an animal model of HIV infection, we found that during the asymptomatic SIV infection dopamine (DA) deficits are early components of central nervous system (CNS) dysfunction. To investigate the role of the DA system in SIV infection and to restore the DA deficiency, we administered selegiline, an agent with DAergic and neuroprotective properties, to SIV-infected monkeys. Selegiline increased DA availability but induced CNS vacuolization, SIV encephalitic lesions, and enhanced CNS viral replication during early SIV infection. The pathological changes seem to be mediated by DA, as treatment with L-DOPA, the precursor of DA, had similar effects. We propose that any natural or induced DAergic dysregulation which results in increased DA availability may potentiate HIV-associated neurological disease (ND). Our findings raise new questions regarding the pathogenesis of HIV-ND and generate concerns about the safety of dopaminergic drugs in the clinical management of HIV-infected patients.
copBerlin
pubSpringer
pmid11271377
doi10.1007/s004010000313